Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii

Yuko Kawabata, Heiichiro Udono, Kiri Honma, Masakatsu Ueda, Hiroshi Mukae, Jun ichi Kadota, Shigeru Kohno, Katsuyuki Yui

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

One of the difficulties in developing an effective malaria vaccine is the antigenic change of the parasite during the life cycle. It is desirable that vaccine-induced protective immunity be effective at different stages of parasite development. Merozoite surface protein 1 (MSP1) is a candidate vaccine antigen against blood-stage malaria, but it is also expressed in the exoerythrocytic forms. It was not known, however, whether the anti-MSP1 immune response is effective against the liver-stage malaria parasite. We generated a recombinant protein of MSP1 fused to heat-shock cognate protein 70 (hsc70) and studied its vaccination effect. When C57BL/6 mice were immunized with the fusion protein prior to challenge infection with Plasmodium yoelii sporozoites, the onset of parasitemia was delayed or no parasitemia was observed. To determine whether this was due to the protective immunity against liver-stage parasites, P. yoelii-specific rRNA in the infected liver was quantitated by real-time reverse transcription-PCR analysis. The level of parasite-specific rRNA was reduced in mice immunized with the fusion protein of MSP1 and hsc70 but not with hsc70 alone, indicating that MSP1-specific immunity can be protective against the exoerythrocytic form of the parasite. Furthermore, the adoptive transfer experiments of immune lymphocytes and serum into naive mice suggested that the protective immunity was dependent on cellular and not humoral immunity. Finally, the vaccine-induced protection was also observed in A/J, C3H, and BALB/c mice, suggesting that MSP1-specific protective immunity at the exoerythrocytic stage can be induced in animals over a wide range of genetic backgrounds.

Original languageEnglish
Pages (from-to)6075-6082
Number of pages8
JournalInfection and Immunity
Volume70
Issue number11
DOIs
Publication statusPublished - Nov 2002
Externally publishedYes

Fingerprint

Merozoite Surface Protein 1
Plasmodium yoelii
Parasites
HSC70 Heat-Shock Proteins
Immunity
Vaccines
Parasitemia
Malaria
Liver
Malaria Vaccines
Sporozoites
Adoptive Transfer
Humoral Immunity
Life Cycle Stages
Inbred C57BL Mouse
Recombinant Proteins
Reverse Transcription
Immune Sera
Vaccination
Proteins

ASJC Scopus subject areas

  • Immunology

Cite this

Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii. / Kawabata, Yuko; Udono, Heiichiro; Honma, Kiri; Ueda, Masakatsu; Mukae, Hiroshi; Kadota, Jun ichi; Kohno, Shigeru; Yui, Katsuyuki.

In: Infection and Immunity, Vol. 70, No. 11, 11.2002, p. 6075-6082.

Research output: Contribution to journalArticle

Kawabata, Yuko ; Udono, Heiichiro ; Honma, Kiri ; Ueda, Masakatsu ; Mukae, Hiroshi ; Kadota, Jun ichi ; Kohno, Shigeru ; Yui, Katsuyuki. / Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii. In: Infection and Immunity. 2002 ; Vol. 70, No. 11. pp. 6075-6082.
@article{1518087f52cd4fe884148d978ffebfba,
title = "Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii",
abstract = "One of the difficulties in developing an effective malaria vaccine is the antigenic change of the parasite during the life cycle. It is desirable that vaccine-induced protective immunity be effective at different stages of parasite development. Merozoite surface protein 1 (MSP1) is a candidate vaccine antigen against blood-stage malaria, but it is also expressed in the exoerythrocytic forms. It was not known, however, whether the anti-MSP1 immune response is effective against the liver-stage malaria parasite. We generated a recombinant protein of MSP1 fused to heat-shock cognate protein 70 (hsc70) and studied its vaccination effect. When C57BL/6 mice were immunized with the fusion protein prior to challenge infection with Plasmodium yoelii sporozoites, the onset of parasitemia was delayed or no parasitemia was observed. To determine whether this was due to the protective immunity against liver-stage parasites, P. yoelii-specific rRNA in the infected liver was quantitated by real-time reverse transcription-PCR analysis. The level of parasite-specific rRNA was reduced in mice immunized with the fusion protein of MSP1 and hsc70 but not with hsc70 alone, indicating that MSP1-specific immunity can be protective against the exoerythrocytic form of the parasite. Furthermore, the adoptive transfer experiments of immune lymphocytes and serum into naive mice suggested that the protective immunity was dependent on cellular and not humoral immunity. Finally, the vaccine-induced protection was also observed in A/J, C3H, and BALB/c mice, suggesting that MSP1-specific protective immunity at the exoerythrocytic stage can be induced in animals over a wide range of genetic backgrounds.",
author = "Yuko Kawabata and Heiichiro Udono and Kiri Honma and Masakatsu Ueda and Hiroshi Mukae and Kadota, {Jun ichi} and Shigeru Kohno and Katsuyuki Yui",
year = "2002",
month = "11",
doi = "10.1128/IAI.70.11.6075-6082.2002",
language = "English",
volume = "70",
pages = "6075--6082",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii

AU - Kawabata, Yuko

AU - Udono, Heiichiro

AU - Honma, Kiri

AU - Ueda, Masakatsu

AU - Mukae, Hiroshi

AU - Kadota, Jun ichi

AU - Kohno, Shigeru

AU - Yui, Katsuyuki

PY - 2002/11

Y1 - 2002/11

N2 - One of the difficulties in developing an effective malaria vaccine is the antigenic change of the parasite during the life cycle. It is desirable that vaccine-induced protective immunity be effective at different stages of parasite development. Merozoite surface protein 1 (MSP1) is a candidate vaccine antigen against blood-stage malaria, but it is also expressed in the exoerythrocytic forms. It was not known, however, whether the anti-MSP1 immune response is effective against the liver-stage malaria parasite. We generated a recombinant protein of MSP1 fused to heat-shock cognate protein 70 (hsc70) and studied its vaccination effect. When C57BL/6 mice were immunized with the fusion protein prior to challenge infection with Plasmodium yoelii sporozoites, the onset of parasitemia was delayed or no parasitemia was observed. To determine whether this was due to the protective immunity against liver-stage parasites, P. yoelii-specific rRNA in the infected liver was quantitated by real-time reverse transcription-PCR analysis. The level of parasite-specific rRNA was reduced in mice immunized with the fusion protein of MSP1 and hsc70 but not with hsc70 alone, indicating that MSP1-specific immunity can be protective against the exoerythrocytic form of the parasite. Furthermore, the adoptive transfer experiments of immune lymphocytes and serum into naive mice suggested that the protective immunity was dependent on cellular and not humoral immunity. Finally, the vaccine-induced protection was also observed in A/J, C3H, and BALB/c mice, suggesting that MSP1-specific protective immunity at the exoerythrocytic stage can be induced in animals over a wide range of genetic backgrounds.

AB - One of the difficulties in developing an effective malaria vaccine is the antigenic change of the parasite during the life cycle. It is desirable that vaccine-induced protective immunity be effective at different stages of parasite development. Merozoite surface protein 1 (MSP1) is a candidate vaccine antigen against blood-stage malaria, but it is also expressed in the exoerythrocytic forms. It was not known, however, whether the anti-MSP1 immune response is effective against the liver-stage malaria parasite. We generated a recombinant protein of MSP1 fused to heat-shock cognate protein 70 (hsc70) and studied its vaccination effect. When C57BL/6 mice were immunized with the fusion protein prior to challenge infection with Plasmodium yoelii sporozoites, the onset of parasitemia was delayed or no parasitemia was observed. To determine whether this was due to the protective immunity against liver-stage parasites, P. yoelii-specific rRNA in the infected liver was quantitated by real-time reverse transcription-PCR analysis. The level of parasite-specific rRNA was reduced in mice immunized with the fusion protein of MSP1 and hsc70 but not with hsc70 alone, indicating that MSP1-specific immunity can be protective against the exoerythrocytic form of the parasite. Furthermore, the adoptive transfer experiments of immune lymphocytes and serum into naive mice suggested that the protective immunity was dependent on cellular and not humoral immunity. Finally, the vaccine-induced protection was also observed in A/J, C3H, and BALB/c mice, suggesting that MSP1-specific protective immunity at the exoerythrocytic stage can be induced in animals over a wide range of genetic backgrounds.

UR - http://www.scopus.com/inward/record.url?scp=0036840312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036840312&partnerID=8YFLogxK

U2 - 10.1128/IAI.70.11.6075-6082.2002

DO - 10.1128/IAI.70.11.6075-6082.2002

M3 - Article

VL - 70

SP - 6075

EP - 6082

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 11

ER -